GSK gets FDA nod for wider use of ovarian cancer drug Zejula

GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

GSK gets FDA nod for wider use of ovarian cancer drug Zejula

GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes ...

Wed 23 Oct 19 from Reuters

U.S. FDA okays wider use of GSK ovarian cancer drug

GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio ...

Wed 23 Oct 19 from Reuters

GSK to sell two vaccines in $1.1 billion deal to focus on newer treatments

GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative ...

Mon 21 Oct 19 from Reuters

GSK to sell two travel vaccines to Danish biotech firm

GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).

Mon 21 Oct 19 from Reuters Health

  • Pages: 1

Bookmark

Bookmark and Share